H.C. Wainwright analyst Edward White lowered the firm’s price target on Cullinan Oncology to $29 from $34 and keeps a Buy rating on the shares. The analyst cites dilution from the capital raise announced today for the target drop. The company announced that is has decided to refocus development of CLN-978 exclusively on autoimmune diseases, the analyst tells investors in a research note. The firm says Cullinan believes CLN-978 has potential to be a first-in-class, off-the- shelf, subcutaneous, disease modifying treatment in autoimmune diseases with a differentiated safety profile.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Management’s Strategic Shift and Capital Raise
- Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
- Cullinan initiated with Outperform on oncology portfolio at William Blair
- Cullinan Oncology initiated with an Outperform at William Blair
- Cullinan Management’s Capital Dilemma: Balancing Equity, Debt, and Partnerships to Avoid Dilution and Restrictions
